Evidence map›Paper›PMID 31455041›Full record

ArticleCancers2019

Elena Bolzacchini, Nunzio Digiacomo, Cristina Marrazzo, Nora Sahnane, Roberta Maragliano, Anthony Gill, Luca Albarello, Fausto Sessa, Daniela Furlan, Carlo Capella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Elusive and Aggressive: UnravelingInternational journal of surgical pathology · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elena BolzacchiniUnit of Oncology, ASST-Lariana, 22100 Como, Italy. elena.bolzacchini@hotmail.it.
Nunzio DigiacomoUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.
Cristina MarrazzoUnit of Oncology, ASST-Sette Laghi, 21100 Varese, Italy.
Nora SahnaneUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.
Roberta MaraglianoUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.
Anthony GillRoyal North Shore Hospital St Leonards, Kolling Institute of Medical Research, University of Sydney and Cancer Diagnosis and Pathology Group, Sydney NSW 2006, Australia.
Luca AlbarelloUnit of Pathology, Ospedale San Raffaele, 20100 Milan, Italy.
Fausto SessaUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.
Daniela FurlanUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.
Carlo CapellaUnit of Pathology, Dept. of Medicine and Surgery and Research Center for the Study of Hereditary and Familial tumors, University of Insubria, 21100 Varese, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal rhabdoid carcinomas (CRbCs) are very rare and aggressive cancers. The

Indexed as

BRAFcolorectal rhabdoid carcinomasCpG island methylator phenotypemicrosatellite instabilitySMARCB1

Identifiers

PMID31455041
PMCPMC6770689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.